SG Americas Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.75M Sell
83,024
-63,939
-44% -$3.5M ﹤0.01% 1113
2026
Q1
$8.3M Sell
146,963
-211,415
-59% -$12.3M 0.01% 852
2025
Q4
$21.3M Buy
358,378
+343,247
+2,269% +$18.7M 0.03% 486
2025
Q3
$819K Sell
15,131
-228,316
-94% -$13.1M ﹤0.01% 1662
2025
Q2
$13.4M Buy
243,447
+150,206
+161% +$8.85M 0.06% 252
2025
Q1
$6.59M Buy
93,241
+87,789
+1,610% +$5.91M 0.02% 402
2024
Q4
$358K Sell
5,452
-818
-13% -$54.8K ﹤0.01% 1638
2024
Q3
$441K Sell
6,270
-1,134
-15% -$94.8K ﹤0.01% 1798
2024
Q2
$610K Sell
7,404
-28,078
-79% -$2.34M ﹤0.01% 1564
2024
Q1
$3.1M Buy
+35,482
New +$3.18M 0.01% 715
2023
Q4
Sell
-4,957
Closed -$439K 3118
2023
Q3
$439K Sell
4,957
-2,893
-37% -$257K 0.01% 1861
2023
Q2
$680K Buy
7,850
+4,919
+168% +$463K 0.01% 1259
2023
Q1
$285K Sell
2,931
-9,614
-77% -$997K ﹤0.01% 2153
2022
Q4
$1.3M Buy
12,545
+10,832
+632% +$1.02M 0.02% 805
2022
Q3
$145K Sell
1,713
-27,364
-94% -$2.44M ﹤0.01% 2573
2022
Q2
$2.41M Sell
29,077
-38,363
-57% -$3.05M 0.03% 637
2022
Q1
$5.2M Buy
67,440
+37,740
+127% +$3.16M 0.04% 403
2021
Q4
$2.62M Buy
29,700
+28,152
+1,819% +$2.32M 0.01% 876
2021
Q3
$120K Sell
1,548
-5,953
-79% -$470K ﹤0.01% 3578
2021
Q2
$626K Sell
7,501
-4,007
-35% -$318K ﹤0.01% 1841
2021
Q1
$869K Sell
11,508
-6,156
-35% -$503K ﹤0.01% 1645
2020
Q4
$1.55M Sell
17,664
-43,792
-71% -$3.47M 0.01% 1250
2020
Q3
$4.68M Sell
61,456
-26,112
-30% -$2.64M 0.03% 372
2020
Q2
$10.8M Buy
87,568
+76,441
+687% +$7.6M 0.09% 157
2020
Q1
$940K Sell
11,127
-3,184
-22% -$274K 0.01% 1346
2019
Q4
$1.21M Sell
14,311
-83,111
-85% -$6.28M 0.01% 1137
2019
Q3
$6.57M Buy
97,422
+82,669
+560% +$6.37M 0.05% 362
2019
Q2
$1.26M Buy
14,753
+931
+7% +$79.6K 0.01% 1284
2019
Q1
$1.23M Buy
+13,822
New +$1.28M 0.01% 1149
2018
Q4
Sell
-28,094
Closed -$2.72M 3059
2018
Q3
$2.72M Buy
28,094
+18,988
+209% +$1.9M 0.02% 932
2018
Q2
$858K Buy
9,106
+1,327
+17% +$116K 0.01% 1587
2018
Q1
$631K Buy
7,779
+1,025
+15% +$88K 0.01% 1722
2017
Q4
$602K Buy
6,754
+5,168
+326% +$449K 0.01% 1724
2017
Q3
$148K Sell
1,586
-347
-18% -$30.7K ﹤0.01% 2850
2017
Q2
$176K Sell
1,933
-22,258
-92% -$2.02M ﹤0.01% 2529
2017
Q1
$2.12M Sell
24,191
-16,765
-41% -$1.49M 0.02% 850
2016
Q4
$3.39M Buy
40,956
+26,995
+193% +$2.32M 0.03% 648
2016
Q3
$1.29M Sell
13,961
-18,411
-57% -$1.73M 0.01% 995
2016
Q2
$2.52M Buy
32,372
+6,794
+27% +$578K 0.02% 717
2016
Q1
$2.11M Sell
25,578
-47,830
-65% -$3.89M 0.02% 827
2015
Q4
$7.69M Sell
73,408
-6,868
-9% -$717K 0.05% 279
2015
Q3
$5.97M Buy
80,276
+27,919
+53% +$3.73M 0.04% 325
2015
Q2
$7.16M Buy
52,357
+4,543
+10% +$563K 0.05% 275
2015
Q1
$5.96M Sell
47,814
-977
-2% -$104K 0.04% 352
2014
Q4
$4.41M Buy
48,791
+24,131
+98% +$2.01M 0.02% 653
2014
Q3
$1.78M Buy
24,660
+22,619
+1,108% +$1.49M 0.01% 926
2014
Q2
$127K Sell
2,041
-15,191
-88% -$918K ﹤0.01% 2239
2014
Q1
$1.18M Buy
17,232
+7,357
+75% +$542K 0.01% 1073
2013
Q4
$694K Buy
9,875
+422
+4% +$28.7K ﹤0.01% 1374
2013
Q3
$683K Buy
+9,453
New +$628K ﹤0.01% 1454

Other funds holding BMRN

SG Americas Securities's BMRN Position: Q2 2026 in Review

SG Americas Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 44% in Q2 2026, selling an estimated $3.5M and leaving 83,024 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

SG Americas Securities first reported a position in BMRN in Q3 2013 and has held it in 50 quarters since. The position peaked at $21.3M in Q4 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SG Americas Securities held 83,024 shares of BioMarin Pharmaceuticals worth $4.75M as of Q2 2026.
  • SG Americas Securities sold 63,939 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.5M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1113 holding.
  • SG Americas Securities first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
  • SG Americas Securities's BioMarin Pharmaceuticals position peaked at $21.3M in Q4 2025.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.